Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.53 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.39 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGAV | P06756 | 1/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30204217 | 1.00 | ACE (0.53) | ACEITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL648059 | 0.86 | KMT2A (0.46) | ACEKMT2AMEN1P2RX7TSHR | |
| SCHEMBL3051120 | 0.84 | ACE (0.38) | ACEKMT2AP2RX7TSHRHSD17B10 | |
| SCHEMBL3051123 | 0.84 | ACE (0.38) | ACEKMT2AP2RX7TSHRHSD17B10 | |
| SCHEMBL31759201 | 0.83 | ACE (0.54) | ACEITGB1ITGA5KMT2AMEN1 | |
| SCHEMBL2954476 | 0.83 | ACE (0.54) | ACEITGB1ITGA5KMT2AMEN1 | |
| SCHEMBL1256527 | 0.81 | ACE (0.49) | ACEITGB1ITGA5HSD17B10 | |
| SCHEMBL713925 | 0.81 | ACE (0.49) | ACEITGB1ITGA5HSD17B10 | |
| SCHEMBL31486522 | 0.81 | ACE (0.49) | ACEITGB1ITGA5HSD17B10 | |
| SCHEMBL4174747 | 0.81 | ACE (0.49) | ACEITGB1ITGA5HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12275723-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-15 | — | — | US | disclosed |
| US-20240400546-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-05 | — | — | US | disclosed |
| US-20240300938-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-12 | — | — | US | disclosed |
| US-20240124435-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-18 | — | — | US | disclosed |
| EP-3802489-A2 | MASP-2 INHIBITORS AND METHODS OF USE | Omeros Corporation (US) | 2021-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124435-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | ACE 414/4885ITGB1 4809/4885ITGA5 3605/4885 |
| US-20240300938-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | ACE 414/4885ITGB1 4809/4885ITGA5 3605/4885 |
| US-20240400546-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | ACE 414/4885ITGB1 4809/4885ITGA5 3605/4885 |
| US-12275723-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | ACE 414/4885ITGB1 4809/4885ITGA5 3605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.